{
    "organizations": [],
    "uuid": "57faae814f0b9b5b2546e338b7f1039750f7b036",
    "author": "",
    "url": "https://www.reuters.com/article/brief-eagle-pharmaceuticals-vasopressin/brief-eagle-pharmaceuticals-vasopressin-anda-accepted-for-filing-by-the-fda-idUSASC09VW6",
    "ord_in_thread": 0,
    "title": "BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16 (Reuters) - Eagle Pharmaceuticals Inc:\n* EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA\n* EAGLE PHARMACEUTICALS INC - PRODUCT IS GENERIC VERSION OF ENDO INTERNATIONAL PLC’S ORIGINAL VASOSTRICT FORMULATION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-16T14:10:00.000+03:00",
    "crawled": "2018-04-16T14:28:09.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "eagle",
        "pharmaceutical",
        "inc",
        "eagle",
        "pharmaceutical",
        "vasopressin",
        "anda",
        "accepted",
        "filing",
        "fda",
        "eagle",
        "pharmaceutical",
        "inc",
        "product",
        "generic",
        "version",
        "endo",
        "international",
        "plc",
        "original",
        "vasostrict",
        "formulation",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}